MedTrace Logo

Nigella Sativa Supplementation in Hyperlipidemia Treatment

NCT06890546 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2025-03-24

No results posted yet for this study

Summary

Hyperlipidemia is defined as an elevation of plasma cholesterol, lipid, or lipoprotein levels above normal due to abnormal fat metabolism or function, and individuals with hyperlipidemia are approximately twice as likely to develop cardiovascular disease. The first approach to treating hyperlipidemia is lifestyle changes, including dietary therapy and physical activity. In addition to traditional methods, treatments also include pharmacological interventions, and research on natural products and complementary therapies is increasing to increase the effectiveness of these treatment approaches. In this context, Nigella Sativa (NS) oil has emerged as a promising natural option in the treatment of hyperlipidemia and obesity in recent years.

The aim of this study was to examine the effects of NS oil supplementation given together with dietary intervention in individuals diagnosed with mild obesity.

The main questions it aims to answer are:

* Does Nigella Sativa supplementation improve blood lipid profiles in overweight or obese individuals?
* Does Nigella Sativa supplementation improve body composition in overweight or obese individuals?

Participants were individuals who were diagnosed with hyperlipidemia according to American Heart Association criteria as a result of medical evaluation by a cardiologist and who were deemed appropriate to use black seed oil supplements. Those who volunteered to participate in the study were included in the study.

The researchers are examining whether there is any effect on biochemical and anthropometric parameters by giving Nigella Sativa supplementation to a group in addition to a low-calorie diet for eight weeks.

Conditions

Interventions

DIETARY_SUPPLEMENT

Nigella Sativa Oil capsule

8 weeks 2 x 900 mg Nigella Sativa oil capsule daily

BEHAVIORAL

Diet

Low calorie diet intervention

Sponsors & Collaborators

  • Istanbul Bilgi University

    lead OTHER

Principal Investigators

  • Hande Seven Avuk, PhD · İstanbul Bilgi University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-01
Primary Completion
2024-02-28
Completion
2025-02-28

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06890546 on ClinicalTrials.gov